Psilocybin for Prolonged Grief Disorder
Part of paid clinical trials in Charlottesville, Virginia.
- Sponsor
- University of Virginia
- Study ID
- NCT06724289
- Phase
- EARLY_PHASE1
- Status
- Recruiting
Conditions
- Prolonged Grief Disorder
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Accepted
Interventions
- Psilocybin 25 mg — DRUG25 mg psilocybin administered to each participant in single arm, open-label trial
- Functional Magnetic Resonance Imaging (fMRI) — DIAGNOSTIC_TESTThere are two "fMRIs" (functional magnetic resonance imaging) that take place 1-14 days before and 1-14 days after psilocybin administration.
Study Details
The primary purpose of this study is to explore the feasibility of conducting a clinical trial on the effects of psilocybin for individuals with prolonged grief disorder (PGD).
Key Dates
- Start date
- Mar 31, 2026
- Status verified
- Mar 2026
- Primary completion
- Aug 31, 2027
- Completion
- Aug 31, 2027
Study Design
- Enrollment
- 12 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Open-label, single arm trial25 mg psilocybin administered to each participant
Primary Outcome Measure
Recruitment Rate [ Time Frame: Through end of enrollment period ]
Central Contacts
- Fatma Wise, PhD(434) 243-0568
- Madison Focht
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Virginia | Charlottesville | Virginia | 22903 | - |
Find similar trials in Charlottesville, VA
By research site